Use of Tranexamic Acid After Vaginal Delivery With Episiotomy a RCT Placebo Control Trail

Sponsor
Assuta Ashdod Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05448456
Collaborator
(none)
150
2
23.7

Study Details

Study Description

Brief Summary

The objective of this study is to assess the effect of TA treatment on decline in Hb levels following vaginal delivery with an episiotomy, compared to a control group not receiving TA.

Condition or Disease Intervention/Treatment Phase
  • Drug: Tranexamic acid
  • Drug: Placebo
Phase 4

Detailed Description

Vaginal delivery is often characterized by excessive blood loss. Normal range of blood loss in uncomplicated vaginal delivery is up to 500 ml. Despite this, most women can adapt due to hemodynamic changes that occur during pregnancy Several factors during labor can promote major blood loss that may be defined as post-partum hemorrhage (PPH) Early PPH (E-PPH) is defined by the World Health Organization as "blood loss from the birth canal in excess of 500 ml during the first 24 hours after delivery E-PPH occurs in up to 6% of births and it is one of the main causes of maternal morbidity and mortality accounting for about 25% of maternal deaths worldwide Among morbidities, E-PPH can lead to post-partum anemia (PPA). PPA incidence is estimated between 50%-80% of women PPA is defined as level of hemoglobin (Hb) of 11 gr/dl one week after delivery Anemia is associated with fatigue, post-partum depression and is a significant health problem in women during the reproductive age .

One of the major causes of E-PPH is perineal trauma. Perineal trauma is present in up to 85% of births either due to an episiotomy or spontaneous tear or a combination of them both During the the second stage of labor, the midwife or the obstetrician may need to make a surgical incision (episiotomy) to increase the diameter of the vaginal outlet and facilitate the baby's birth This procedure is done with scissors or scalpel and requires repair by suturing (14). In the United States, episiotomy rate was 11.6% in 2012 In a study published by Alvarez et al in 2017, the average reduction in Hb was 1.46 ± 1.09 g/dl following vaginal delivery with a second degree tear but without an episiotomy and 2.07 ± 1.24 following vaginal delivery with an episiotomy and no perineal tear. The greatest reduction in Hb occurred among women with episiotomy and a third or fourth degree tear with a decrease of 3.1 ± 1.32 g/dl.

Different strategies have been described for preventing and treatment PPH, including active management of the third stage of labor, among them uterine massage and controlled cord traction in addition to oxytocin and the use of Tranexamic acid (TA) as PPH treatment Tranexamic acid (TA) is a lysine analog, which acts as an antifibrinolytic via competitive inhibition to the binding of plasmin and plasminogen to fibrin. TA reaches peak plasma concentration immediately after intravenous administration A meta-analysis evaluated the use of tranexamic acid after vaginal delivery for prevention of primary PPH. When used as prophylaxis within 10 min after vaginal delivery usually at the dose of 1 g IV, in addition to standard prophylaxis with oxytocin, tranexamic acid reduced the risk of primary PPH and the mean post-partum blood loss However there are no studies that evaluated the impact of TA on blood loss after vaginal deliveries with an episiotomy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
150 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
Use of Tranexamic Acid After Vaginal Delivery With Episiotomy a RCT Placebo Control Trail
Anticipated Study Start Date :
Jul 20, 2022
Anticipated Primary Completion Date :
Jul 10, 2023
Anticipated Study Completion Date :
Jul 10, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Hexakakapron group

women with an episiotomy after vaginal delivery

Drug: Tranexamic acid
1 gram of tranexamic acid in 100 ml of 0.9% normal saline
Other Names:
  • Hexakapron
  • Placebo Comparator: control group

    women with an episiotomy after vaginal delivery

    Drug: Placebo
    100 ml of 0.9% normal saline
    Other Names:
  • saline
  • Outcome Measures

    Primary Outcome Measures

    1. Delta Hb levels [24 hours from delivery]

      Delta-Hb (Hb level prior delivery - Hb levels 24 h after birth)

    Secondary Outcome Measures

    1. PPH rate [24 hours from delivery]

      early post partum hemorrhage

    2. Uterotonics use [24 hours from delivery]

      Use of additional uterotonics drugs(other than oxytocin)- dichotomies scale, yes or no

    3. Blood transfusion [72 hours from delivery]

      Use of Blood packed cells during hospitalization, dichotomies scale - yes or no

    4. hospital admission [120 hours from delivery]

      Number of hospital admission days

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. women aged 18-45

    2. 37-42 weeks gestation

    3. Singleton pregnancy

    4. Cephalic presentation

    Exclusion Criteria:
    1. Any contra-indication for vaginal birth

    2. PPH risk factors

    3. Dysfunctional labor

    4. Over distended uterus (macrosomia ,Polyhydramnios,multiple gestation)

    5. Grand multiparity

    6. Chorioamnionitis

    7. Precipitous labor

    8. Operative delivery

    9. Prolonged second stage

    10. Previous pph

    11. Preeclampsia

    12. Placental abruption

    13. Previous cesarean delivery

    14. Thrombophilia or coagulopathy

    15. Allergy to TA

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assuta Ashdod Hospital

    Investigators

    • Principal Investigator: Atara De Porto Amrany, MD, Samson Assuta Ashdod University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Eran Brazilay, MD PhD, Head of the obstetric and gynecologic ultrasound unit, Assuta Ashdod Hospital
    ClinicalTrials.gov Identifier:
    NCT05448456
    Other Study ID Numbers:
    • 0138-21-AA
    First Posted:
    Jul 7, 2022
    Last Update Posted:
    Jul 20, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 20, 2022